FINWIRES · TerminalLIVE
FINWIRES

GMS Group to Acquire 1.54 Million Treasury Shares from Subsidiaries via In-Kind Dividend

By

Nissei Plastic Industrial and Toyo Innovex, both wholly owned subsidiaries of GMS Group (TYO:544A), have resolved at their extraordinary general meetings to distribute all GMS Group shares they hold back to the parent company as a dividend in kind.

The injection moulding machine maker said the move is required under the Companies Act, which mandates that subsidiaries dispose of parent company shares within an appropriate period.

As a result, GMS Group will acquire 1.54 million treasury shares on May 28. Following the acquisition, total issued shares excluding treasury shares will decrease to 69.4 million shares, a reduction of 1.54 million shares.

Related Articles

Asia

LY Corp. Clears Thai Regulatory Hurdle for Line Man Acquisition

LY Corp. (TYO:4689) received notification from Thai authorities on May 14, confirming that no approvals or permits are required for the additional acquisition of shares in Line Man Corp. through its subsidiary.The company had already integrated Line Man as a consolidated subsidiary on September 30, 2025, while awaiting the final conclusion of the cross-border regulatory review. With the statutory clearance now finalized, the Tokyo-based tech firm plans to formally execute and settle the additional share acquisition by August 2026.LY Corp. projects holding over 81 million Line Man Corp. shares, giving them 60.9% of the voting rights, once the transaction is finished.

$TYO:4689
Asia

Kissei Pharmaceutical Submits NDA in Japan for AML Drug Olutasidenib

Kissei Pharmaceutical (TYO:4547) has submitted a new drug application in Japan seeking manufacturing and marketing approval for olutasidenib, a treatment for relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation.The drug works by inhibiting the IDH1 metabolic enzyme to restore normal cell differentiation and was originally discovered by Forma Therapeutics, according to at Tokyo bourse filing on Wednesday.Kissei acquired exclusive development and sales rights for Japan, South Korea, and Taiwan from Rigel Pharmaceuticals in September 2024, following olutasidenib's U.S. approval in December 2022.Kissei remains focused on developing new treatments for rare diseases with limited therapeutic options.The submission's impact is already reflected in the company's consolidated financial forecast for the fiscal year ending March 31, 2027.

$TYO:4547
Asia

Mrs. Bectors Food Specialities' Consolidated Net Profit Climbs in Fiscal Q4

Mrs. Bectors Food Specialities' (NSE:BECTORFOOD, BOM:543253) consolidated net profit rose to 354.1 million Indian rupees in the fiscal fourth quarter ended March 31 from 342.8 million rupees a year ago.Earnings per share climbed to 1.15 rupees from 1.12 rupees a year earlier, the bakery products manufacturer said in a filing to the Indian stock exchanges on Wednesday.Revenue from operations in fiscal Q4 was up at 4.86 billion rupees from 4.46 billion rupees a year ago.The company's board recommended a final dividend of 0.70 rupees per equity share, having a face value of 2 rupees each, for the fiscal year ended March 31.

$BOM:543253$NSE:BECTORFOOD